Cell-permeable leukotriene A4 (LTA4) hydrolase inhibitor which suppresses the production of LTB4. It is implicated in the pathogenesis of many diseases including inflammatory bowel disease and psoriasis.
Cell-permeable leukotriene A4 (LTA4) hydrolase inhibitor which suppresses the production of LTB4. It is implicated in the pathogenesis of many diseases including inflammatory bowel disease and psoriasis.
Cell-permeable leukotriene A4 (LTA4) hydrolase inhibitor which suppresses the production of LTB4. It is implicated in the pathogenesis of many diseases including inflammatory bowel disease and psoriasis.
Cell-permeable leukotriene A4 (LTA4) hydrolase inhibitor which suppresses the production of LTB4. It is implicated in the pathogenesis of many diseases including inflammatory bowel disease and psoriasis.
Cell-permeable leukotriene A4 (LTA4) hydrolase inhibitor which suppresses the production of LTB4. It is implicated in the pathogenesis of many diseases including inflammatory bowel disease and psoriasis.
Cell-permeable leukotriene A4 (LTA4) hydrolase inhibitor which suppresses the production of LTB4. It is implicated in the pathogenesis of many diseases including inflammatory bowel disease and psoriasis.
Product introduction:Texas red-x,SE can be used to generate bright red fluorescent bioconjugates. This reactive dye has an additional 7-atom aminohexanoyl interval (x) between the fluorescent group and the succinimidyl ester group. This interval
Product introduction:Texas red-x,SE can be used to generate bright red fluorescent bioconjugates. This reactive dye has an additional 7-atom aminohexanoyl interval (x) between the fluorescent group and the succinimidyl ester group. This interval
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88 , causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activityIn VitroST2825 blocks IL-1R/TLR signaling by